Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 7
2003 10
2004 1
2005 4
2006 10
2007 15
2008 10
2009 10
2010 9
2011 12
2012 13
2013 14
2014 13
2015 16
2016 17
2017 10
2018 14
2019 5
2020 11
2021 14
2022 8
2023 8
2024 9
2025 18
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

227 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR 3rd, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ. Maertens JA, et al. Lancet. 2016 Feb 20;387(10020):760-9. doi: 10.1016/S0140-6736(15)01159-9. Epub 2015 Dec 10. Lancet. 2016. PMID: 26684607 Clinical Trial.
The SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease. METHODS: This was a phase 3, double-blind, global multicentre, comparative-group study. ...Drug-related adverse events were reported in 109 (42%) pat …
The SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease. METHODS: …
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.
Maertens JA, Rahav G, Lee DG, Ponce-de-León A, Ramírez Sánchez IC, Klimko N, Sonet A, Haider S, Diego Vélez J, Raad I, Koh LP, Karthaus M, Zhou J, Ben-Ami R, Motyl MR, Han S, Grandhi A, Waskin H; study investigators. Maertens JA, et al. Lancet. 2021 Feb 6;397(10273):499-509. doi: 10.1016/S0140-6736(21)00219-1. Lancet. 2021. PMID: 33549194 Clinical Trial.
BACKGROUND: Voriconazole has been recommended as primary treatment for patients with invasive aspergillosis. Intravenous and tablet formulations of posaconazole that have improved systemic absorption could be an effective alternative to voriconazole. We aimed to ass …
BACKGROUND: Voriconazole has been recommended as primary treatment for patients with invasive aspergillosis. Intravenous and tablet f …
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Herbrecht R, et al. N Engl J Med. 2002 Aug 8;347(6):408-15. doi: 10.1056/NEJMoa020191. N Engl J Med. 2002. PMID: 12167683 Free article. Clinical Trial.
BACKGROUND: Voriconazole is a broad-spectrum triazole that is active against aspergillus species. We conducted a randomized trial to compare voriconazole with amphotericin B for primary therapy of invasive aspergillosis. ...Voriconazole-treated patients had s …
BACKGROUND: Voriconazole is a broad-spectrum triazole that is active against aspergillus species. We conducted a randomized trial to …
Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.
Takesue Y, Hanai Y, Oda K, Hamada Y, Ueda T, Mayumi T, Matsumoto K, Fujii S, Takahashi Y, Miyazaki Y, Kimura T; Japanese Antimicrobial Therapeutic Drug Monitoring Guideline Committee. Takesue Y, et al. Clin Ther. 2022 Dec;44(12):1604-1623. doi: 10.1016/j.clinthera.2022.10.005. Epub 2022 Nov 22. Clin Ther. 2022. PMID: 36424314 Free article.
PURPOSE: Voriconazole, an antifungal drug, is metabolized by a cytochrome P450 isozyme. Increased adverse effects are observed in Asians because of the high rate of poor metabolizers. ...
PURPOSE: Voriconazole, an antifungal drug, is metabolized by a cytochrome P450 isozyme. Increased adverse effects are observed in Asi …
Natamycin versus voriconazole for fungal keratitis.
Retamal J, Ordenes-Cavieres G, Grau-Diez A. Retamal J, et al. Medwave. 2018 Dec 18;18(8):e7388. doi: 10.5867/medwave.2018.08.7387. Medwave. 2018. PMID: 30562337 English, Spanish.
Topical antifungals, particularly natamycin and voriconazole, are considered effective, but it is not clear which one is the best treatment alternative. ...We concluded natamycin probably is associated with better visual acuity after infection, and it prevents corneal perf …
Topical antifungals, particularly natamycin and voriconazole, are considered effective, but it is not clear which one is the best tre …
Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial.
Sehgal IS, Agarwal R, Dhooria S, Prasad KT, Muthu V, Aggarwal AN, Rudramurthy SM, Garg M, Chakrabarti A. Sehgal IS, et al. Lancet Infect Dis. 2026 Mar;26(3):239-249. doi: 10.1016/S1473-3099(25)00537-7. Epub 2025 Oct 29. Lancet Infect Dis. 2026. PMID: 41175884 Clinical Trial.
Voriconazole was associated with significantly more treatment-related adverse events than itraconazole (55% [32 of 58] of participants receiving voriconazole vs 34% [20 of 58] receiving itraconazole, p=0.025). There were four deaths, all in the voriconazole g …
Voriconazole was associated with significantly more treatment-related adverse events than itraconazole (55% [32 of 58] of participant …
Voriconazole exposure and risk of cutaneous squamous cell carcinoma among lung or hematopoietic cell transplant patients: A systematic review and meta-analysis.
Tang H, Shi W, Song Y, Han J. Tang H, et al. J Am Acad Dermatol. 2019 Feb;80(2):500-507.e10. doi: 10.1016/j.jaad.2018.08.010. Epub 2018 Aug 18. J Am Acad Dermatol. 2019. PMID: 30130598 Free article.
BACKGROUND: Current evidence about the association between voriconazole and risk of cutaneous squamous cell carcinoma (SCC) remains inconsistent. OBJECTIVE: To assess the association between voriconazole use and risk of SCC. ...Voriconazole use was not associ …
BACKGROUND: Current evidence about the association between voriconazole and risk of cutaneous squamous cell carcinoma (SCC) remains i …
Utility of voriconazole therapeutic drug monitoring: a meta-analysis.
Luong ML, Al-Dabbagh M, Groll AH, Racil Z, Nannya Y, Mitsani D, Husain S. Luong ML, et al. J Antimicrob Chemother. 2016 Jul;71(7):1786-99. doi: 10.1093/jac/dkw099. Epub 2016 May 10. J Antimicrob Chemother. 2016. PMID: 27165788
BACKGROUND: Voriconazole therapeutic drug monitoring (TDM) is increasingly used in clinical practice. However, the utility of voriconazole TDM to guide therapy remains uncertain and controversial. We conducted a meta-analysis of studies assessing the relationship be …
BACKGROUND: Voriconazole therapeutic drug monitoring (TDM) is increasingly used in clinical practice. However, the utility of vori …
Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.
Jørgensen KJ, Gøtzsche PC, Dalbøge CS, Johansen HK. Jørgensen KJ, et al. Cochrane Database Syst Rev. 2014 Feb 24;2014(2):CD004707. doi: 10.1002/14651858.CD004707.pub3. Cochrane Database Syst Rev. 2014. PMID: 24563222 Free PMC article.
In the first trial, voriconazole was significantly inferior to liposomal amphotericin B according to the trial authors' prespecified criteria. ...The third trial failed to find a difference in fungal free survival or invasive fungal infections at 180 days when voriconaz …
In the first trial, voriconazole was significantly inferior to liposomal amphotericin B according to the trial authors' prespecified …
Voriconazole versus amphotericin B in cancer patients with neutropenia.
Jørgensen KJ, Gøtzsche PC, Johansen HK. Jørgensen KJ, et al. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004707. doi: 10.1002/14651858.CD004707.pub2. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2014 Feb 24;(2):CD004707. doi: 10.1002/14651858.CD004707.pub3. PMID: 16437492 Updated.
In the first trial, voriconazole was significantly inferior to liposomal amphotericin B according to the authors' prespecified criteria. ...For treatment of aspergillosis, there are no trials that have compared voriconazole with amphotericin B given under optimal co …
In the first trial, voriconazole was significantly inferior to liposomal amphotericin B according to the authors' prespecified criter …
227 results